AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Genentech has 25.8 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Genentech (kadcyla.com)
Kadcyla.com is a fortress of legal compliance and clinical rigidity, where substance significantly outweighs signal. The site suffers from the typical ‘pharma-template’ malaise, but the density of actual trial data makes it nearly immune to traditional BS. Its only ‘bullshit’ is the mechanical repetition of marketing slogans required to make toxic chemotherapy sound like a ‘journey’.
Add specific ClinicalTrials.gov registration numbers (NCT identifiers) directly beneath the three-year trial outcome images to move from ‘trust theatre’ to forensic validation. Differentiate the H1 headings on the indication sub-pages; using the same ‘2 cancer-fighting agents’ slogan on both Early and Metastatic pages creates a commodity template feel. Integrate outbound links to the peer-reviewed publications for the KATHERINE and EMILIA trials to provide a verification path for the claimed success rates. Address the backend metadata discrepancy where a review_count is flagged without associated proof links to eliminate technical trust theatre signals.
The site exhibits high information density, particularly regarding clinical outcomes such as the 88 percent cancer-free rate among 743 participants in the study. Contrast this with the ‘What will your treatment journey look like?’ H1, which leans into patient journey fluff but is immediately anchored by specific medical indications. Substantiative passages define the precise dosing schedule—14 cycles every 3 weeks—and the exact duration of infusions (90 then 30 minutes). BS points in this pillar are solely derived from the verbatim repetition of the ‘2 cancer-fighting agents in 1 drug’ claim across multiple sub-pages without evolving the messaging.
A site without a coherent link graph forces AI to guess which pages matter. Reveal your real semantic graph and see how your domain is actually mapped by machine logic.
There is zero semantic drift between the homepage signal and the sub-page evidence. The homepage H1 introduces the ‘treatment journey’ concept, which is logically expanded upon in the ‘Taking KADCYLA’ sections of the Early and Metastatic breast cancer pages. Each indication sub-page delivers evidence specific to its audience, such as the 50 percent lower chance of recurrence for early cancer and distinct side effect lists for metastatic cases. The heading hierarchy (H1-H5) is exceptionally consistent across the site, ensuring the Important Safety Information is never buried beneath marketing slogans.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The metadata across all four pages displays a review_count of 2 alongside a proof_links_count of 0, which triggers a forensic trust theatre penalty. In a pharmaceutical context, consumer reviews are rare and often replaced by clinical data; however, the presence of a ‘review count’ in the site’s schema without linked verification paths represents a technical BS signal. This mismatch suggests either a legacy code remnant or an unverified social proof mechanism that lacks the rigor of the rest of the site’s medical claims.
Proof density is high, with the site delivering granular technical specifications including infusion durations, birth control timelines (7 months), and clinical recurrence percentages. The ratio of fluff to substance is skewed heavily toward substance, as over 50 percent of the body text is dedicated to required safety disclosures and trial outcomes. Every bold claim regarding cancer recurrence or mechanism of action is paired with a specific percentage or a reference to FDA-approved diagnostic criteria.
To review a full competitive diagnostic applied to an enterprise level technical SEO agency, including a direct comparison against Dejan, examine the complete executive audit. View the iPullRank Executive SEO Strategy Dashboard for a practical example of how perception gaps, value prop drift, and audience misalignment are surfaced in real audits.
The site relies on a rigid, formulaic template common to the Genentech portfolio, including standard sections like ‘Financial support options’ and ‘Starting the conversation.’ While the MOA (Antibody-Drug Conjugate) is a unique therapeutic approach, the marketing headline ‘2 cancer-fighting agents in 1 drug’ is a simplified value proposition that borders on industry cliché. These template fingerprints are expected for regulatory compliance but result in a commodity feel that lacks unique digital positioning. Despite this, the high specificity of the clinical data prevents the brand from being easily swappable with a generic competitor.
The authority of the site is established through the Genentech corporate schema, which includes a physical address in South San Francisco and a dedicated customer service contact point. There is a lack of specific Person schema for clinical leadership, though this is typical for drug-specific brand sites which prioritize regulatory approval status over individual expertise. The technical implementation is robust, with a clear heading hierarchy and a pharmacovigilance mechanism for reporting side effects to the FDA and Genentech.
The performance claims made on the site are among the most substantiated in any industry audit, citing specific three-year cancer-free rates of 88 percent versus 77 percent for the control group. These assertions are backed by a trial population count of 743 people and a clear acknowledgment of the study’s current limitations, specifically regarding long-term survival data. The site avoids the ‘miracle cure’ tone, maintaining a sober marketing stance that prioritizes safety information and the role of FDA-approved testing for patient selection.
Medical Devices, Pharma & Biotech BS: Genentech (kadcyla.com)
The content perfectly aligns with the Pharma & Biotech category, specifically focusing on oncology treatment for HER2-positive breast cancer. The presence of extensive Safety Information and clinical trial results confirms its classification as a highly regulated medical drug site.
Your site's meaning is determined by its graph, not its menus. Review the Internal Linking Architecture Framework to see how AI interprets nodes, edges, and authority flow inside your domain.
“The low score of 15 reflects the high regulatory burden of pharmaceutical sites, which mandates substance (Safety Information, trial percentages, and specific dosing timelines). Points were only lost for the repetition of the '2-in-1' value proposition across indication pages and a trust theatre flag triggered by the presence of a review count without verified proof links in the metadata. The identity and authority of Genentech are fully supported by robust Organization schema and FDA-compliant disclosures.”